Last reviewed · How we verify
Placebo for V114
This is a placebo control with no active pharmacological mechanism.
This is a placebo control with no active pharmacological mechanism. Used for Control arm in V114 clinical trial (V114 is a pneumococcal vaccine candidate).
At a glance
| Generic name | Placebo for V114 |
|---|---|
| Sponsor | Merck Sharp & Dohme LLC |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
Placebo is an inert substance used as a control in clinical trials to establish the efficacy of the active investigational drug V114 through comparison. It contains no active pharmaceutical ingredient and serves to blind trial participants and assessors to treatment assignment.
Approved indications
- Control arm in V114 clinical trial (V114 is a pneumococcal vaccine candidate)
Common side effects
Key clinical trials
- Safety, Tolerability, and Immunogenicity of V110 or V114 Co-administered With a Booster Dose of mRNA-1273 in Healthy Adults (V110-911) (PHASE3)
- A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 When Administered Concomitantly With Influenza Vaccine in Healthy Adults 50 Years of Age or Older (V114-021/PNEU-FLU) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo for V114 CI brief — competitive landscape report
- Placebo for V114 updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI